반응식
Cl[C:2]1[CH:3]=[CH:4][C:5]2[N:6]([C:8]([CH2:11][C:12]3[CH:13]=[CH:14][C:15]4[N:16]([CH:18]=[CH:19][N:20]=4)[CH:17]=3)=[CH:9][N:10]=2)[N:7]=1.[CH2:21]([N:23]1[CH:27]=[C:26](B2OC(C)(C)C(C)(C)O2)[CH:25]=[N:24]1)[CH3:22]>>[CH2:21]([N:23]1[CH:27]=[C:26]([C:2]2[CH:3]=[CH:4][C:5]3[N:6]([C:8]([CH2:11][C:12]4[CH:13]=[CH:14][C:15]5[N:16]([CH:18]=[CH:19][N:20]=5)[CH:17]=4)=[CH:9][N:10]=3)[N:7]=2)[CH:25]=[N:24]1)[CH3:22]참가 물질
3
실험 절차
The title compound was prepared in analogy to Example 9 using chloro-3-imidazo[1,2-a]pyridin-6-ylmethyl-imidazo[1,2-b]pyridazine (Example 74) instead of (rac)-(6-chloro-imidazo[1,2-b]pyridazin-3-yl)-imidazo[1,2-a]pyridin-6-yl-methanol (Stage 9.1) and 1-ethyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole instead of 1-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (tR 2.88 min (conditions 3), MH+=344.1).
출처 및 근거
- ORD 기록
- ord-01dd41874a2c4ff6a91e542a6b7c7136
- 출처 데이터셋
- uspto-grants-2014_09
- 특허 번호
- US08822468B2
연결된 노트
불러오는 중…